|Poll|November 11, 2014

Mini-quiz: Suicide Risk After Hospitalization

What percentage of patients hospitalized for depression eventually die by suicide? Learn more in this quiz.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

ByCharles Debattista, MD

July 10th 2026

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

BySandhya Prashad, MD

July 9th 2026

Potential of GABAergic Medications in MDD

ByGustavo Alva, MD, DFAPA,Jason Kellogg, MD

July 2nd 2026

The Top 10 Misleading Claims About Antidepressants

ByRoger S. McIntyre, MD, FRCPC,Ronald W. Pies, MD

July 2nd 2026

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Suicide Risk After Hospitalization

Related Content

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

Potential of GABAergic Medications in MDD

The Top 10 Misleading Claims About Antidepressants

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD

Filling the Gap Between IV Ketamine Clinical Use and Evidence-Based Standards

Developments in Cannabis Withdrawal and Addiction Treatment

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression